title: PRP-1 protective effect against central and peripheral neurodegeneration following n. ischiadicus transection.
abstract: We investigated the action of the new hypothalamic proline-rich peptide (PRP-1), normally produced by neurosecretory cells of hypothalamic nuclei (NPV and NSO), 3 and 4 weeks following rat sciatic nerve transection. The impulse activity flow of interneurons (IN) and motoneurons (MN) on stimulation of mixed (n. ischiadicus), flexor (n. gastrocnemius--G) and extensor (n. peroneus communis--P) nerves of both injured and symmetric intact sides of spinal cord (SC) was recorded in rats with daily administration of PRP-1 (for a period of 3 weeks) and without it (control). On the injured side of SC in control, there were no responses of IN and MN on ipsilateral G and P stimulation, while responses were elicited on contralateral nerve stimulation. The neuron responses on the intact side of SC were revealed in a reverse ratio. Thus, there were no effects upon stimulation of the injured nerve distal stump in the control because of the absence of fusion between transected nerve stumps. This was also testified by the atrophy of the distal stump and the absence of motor activity of the affected limb. In PRP-1-treated animals, the responses of SC IN and MN in postaxotomy 3 weeks on the injured side of SC at ipsilateral nerve stimulation and on the intact side at contralateral nerve stimulation were recorded because of the obvious fusion of the severed nerve stumps. The histochemical data confirmed the electrophysiological findings. Complete coalescence of transected fibers together with restoration of the motor activity of the affected limb provided evidence for reinnervation on the injured side. Thus, it may be concluded that PRP-1 promotes nerve regeneration and may be used clinically to improve the outcome of peripheral nerve primary repair.
authors.affiliation: Buniatian Institute of Biochemistry NAS RA, 5/1 Sevag str, 375014, Yerevan, Republic of Armenia. galoyan@sci.am
authors.forename: Armen A
authors.initials: AA
authors.lastname: Galoyan
authors.forename: John S
authors.initials: JS
authors.lastname: Sarkissian
authors.forename: Ruben M
authors.initials: RM
authors.lastname: Sulkhanyan
authors.forename: Vergine A
authors.initials: VA
authors.lastname: Chavushyan
authors.forename: Zubeida A
authors.initials: ZA
authors.lastname: Avetisyan
authors.forename: Zaruhi E
authors.initials: ZE
authors.lastname: Avakyan
authors.forename: Anoush J
authors.initials: AJ
authors.lastname: Gevorgyan
authors.forename: Davit O
authors.initials: DO
authors.lastname: Abrahamyan
authors.forename: Yuri Kh
authors.initials: YKh
authors.lastname: Grigorian
mesh_terms: D000465:Algorithms; D000818:Animals; D002490:Central Nervous System / Q000473:pathology*; D004558:Electric Stimulation; D004594:Electrophysiology; D005260:Female; D006614:Hindlimb / Q000294:innervation / Q000502:physiology; D008297:Male; D009412:Nerve Fibers / Q000502:physiology; D009416:Nerve Regeneration / Q000187:drug effects; D019636:Neurodegenerative Diseases / Q000473:pathology* / Q000517:prevention & control*; D018696:Neuroprotective Agents; D010455:Peptides / Q000494:pharmacology*; D010525:Peripheral Nerves / Q000473:pathology*; D055232:Proline-Rich Protein Domains; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000502:physiology
chemical_list: D018696:Neuroprotective Agents; D010455:Peptides